- Previous Close
0.0420 - Open
0.0420 - Bid 0.0420 x --
- Ask 0.0430 x --
- Day's Range
0.0400 - 0.0440 - 52 Week Range
0.0400 - 0.1250 - Volume
710,859 - Avg. Volume
598,749 - Market Cap (intraday)
41.685M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 27, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.60
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. Neurotech International Limited was incorporated in 2016 and is based in Nedlands, Australia.
www.neurotechinternational.comRecent News: NTI.AX
View MorePerformance Overview: NTI.AX
Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTI.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTI.AX
View MoreValuation Measures
Market Cap
41.68M
Enterprise Value
30.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.58k
Price/Book (mrq)
3.50
Enterprise Value/Revenue
15.31k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-159.54%
Return on Assets (ttm)
-37.29%
Return on Equity (ttm)
-63.92%
Revenue (ttm)
3.18M
Net Income Avi to Common (ttm)
-5.07M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.63M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.42M